

# Review of: "Retinal Vasculitis Following COVID-19 Infection: A Systematic Review"

Ali Younis<sup>1</sup>

<sup>1</sup> University of Mosul

**Potential competing interests:** No potential competing interests to declare.

This paper addresses an interesting topic: retinal vasculitis following COVID-19 infection. However, some concerns need to be pointed out:

The main limitation of this systematic review is the small number of patients and the fact that most of the studies were case reports.

Regarding the objectives of this study, you mentioned that you want to analyse the systemic features of those cases with retinal vasculitis; however, nothing is mentioned about that in the results.

Regarding methodology, for each keyword you used in the review, you must include all synonyms. For example, sars-cov-2 and coronavirus 2019 should be searched for while looking for covid-19.

Also, I would suggest searching a second database, like Google Scholar. Another point is how the screening process was carried out. How many reviewers conducted the screening? Two independent reviewers are usually needed to perform screening.

The inclusion and exclusion criteria should also be more clarified. Another point to be clarified is the basis on which COVID-19 was diagnosed. The demographic features, comorbidities, and COVID-19 severity should also be pointed out.

It is not clarified what is exactly meant by the time from onset of the vasculitis following COVID-19 infection (diagnosis, onset of symptoms, or something else?).

In the discussion, the first paragraph extensively discussed the occurrence of systemic vasculitis complicating COVID-19 infection; however, all the cases included in the systematic review were isolated retinal vasculitis and not part of systemic vasculitis. Also, there was a detailed discussion about retinal vascular occlusion (noninflammatory) in the manuscript published by Yeo and his colleagues. It would be better to make a comparison with studies addressing retinal vasculitis complicating COVID-19 infection. Furthermore, you have talked about retinal vasculitis as a complication of the COVID-19 vaccine, which is not a part of your study, so it would be better to remove it or include retinal vasculitis as a complication of COVID-19 vaccination in your study.

You should mention the limitations of your study, like small sample size and the inclusion of case reports mainly.

